Local drugstore chain Mercury Drug Corp., in partnership with AstraZeneca and Diabetes Philippines, said on Wednesday that it aims to delay the “end cases” of Chronic Kidney Disease (CKD) by offering early detection through free Urine Albumin-to-Creatinine Ratio (UACR) screening.
“Our goal is to be able to find out who among these patients or Filipinos may potentially have kidney disease because kidney disease is asymptomatic,” AstraZeneca Philippines Medical Affairs Director Cyril Joseph P. Tolosa told BusinessWorld in an interview.
Support authors and subscribe to content
This is premium stuff. Subscribe to read the entire article.
Login if you have purchased
